Vistagen Therapeutics (NASDAQ:VTGN) Issues Quarterly Earnings Results

Vistagen Therapeutics (NASDAQ:VTGN) released its quarterly earnings data on Thursday. The company reported ($0.46) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.02, Zacks reports. Vistagen Therapeutics had a negative return on equity of 36.35% and a negative net margin of 4,521.71%.

Vistagen Therapeutics Price Performance

Shares of NASDAQ VTGN opened at $2.97 on Friday. Vistagen Therapeutics has a 1 year low of $2.22 and a 1 year high of $5.74. The firm has a 50-day simple moving average of $2.81 and a two-hundred day simple moving average of $2.99.

Vistagen Therapeutics Company Profile

Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.